ixlayer
ixlayer.com
Biotechnology
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
A Direct-to-Patient Platform Built for Biopharma ixlayer’s unified direct-to-patient platform, helps biopharma transform the patient experience with integrated AI capabilities. Simplify and Accelerate the Connection to Care 42% Scheduled a visit with a physician after receiving abnormal lab results.
News
ixlayer Survey Reveals 94% of Pharma Leaders Currently or Plan to Run Direct-to-Consumer Programs Within the Next Year PharmExec
Pharma leaders embrace direct-to-consumer strategies, with 94% exploring DTC programs to enhance patient experience and accelerate treatment access.
Read more
Report
ixlayer Launches Informed Pain Care, Expanding Access to Digital Acute Pain Evaluation Nationwide
ixlayer Launches Informed Pain Care, Expanding Access to Digital Acute Pain Evaluation Nationwide Patients Can Now Connect with Licensed Clinicians through the Informed Pain Care Platform to Receive Timely Evaluation and Access to Non-Opioid Treatment Opt
Read more
Report
ixlayer Launched Informed Pain Care, Expanding Access to Digital Acute Pain Evaluation Nationwide
Read more
Report
ixlayer Appoints Helmut Osorio as General Manager to Accelerate Direct-to-Patient Growth for Biopharma
ixlayer Appoints Helmut Osorio as General Manager to Accelerate Direct-to-Patient Growth for Biopharma Former Regeneron, Pfizer and Purdue Pharma commercial leader brings deep expertise as ixlayer expands its award-winning direct-to-patient platform SAN F
Read more
Report
ixlayer Appoints Helmut Osorio as General Manager to Accelerate Direct-to-Patient Growth for Biopharma
Read more
Report
The Fragmented Middle
A practical POV for biopharma operators on why patient momentum often stalls after intake, and how a connected operating layer can keep direct-to-patient journeys moving from education and testing through access, fulfillment, and follow-through.
Read more
Report
Connection to care is the new bar in direct-to-patient
Connection to care is the new bar in direct-to-patient Biopharma direct-to-patient operators have become good at one part of the problem. Campaigns can now scale awareness quickly, capture interest reliably, and move people into branded education channels
Read more
Report
From Awareness to Care Progression: Why the Funnel Isn't Fixed at the First Click
From Awareness to Care Progression: Why the Funnel Isn't Fixed at the First Click Biopharma teams know how to generate awareness. Search demand, social engagement, education campaigns, disease content-many teams are strong at these moves. The harder quest
Read more
Report
Moving Pharmacy Upstream: The Strength of Earlier Pharmacy Integration
Moving Pharmacy Upstream: The Strength of Earlier Pharmacy Integration For pharmaceutical marketers, campaign performance often boils down to one metric: time to treatment. Every additional step between awareness and first-dose is friction that facilitate
Read more
Report
New Performance Data Shows Why Pharma Is Reallocating Spend Toward Direct-to-Patient Care
New Performance Data Shows Why Pharma Is Reallocating Spend Toward Direct-to-Patient Care Pharmaceutical brands are increasingly shifting investment toward direct-to-patient (DTP) care models as a response to measurable performance. New data from ixlayer
Read more
Report
Show more news
People
Pouria Sanae
Executive Officer, Director
Poorya Sabounchi
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
3
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Atherton
United States
HQ
San Francisco
United States
Corporate Office - West Coast
447 Sutter Street, Suite 405, PMB 53, San Francisco, CA 94108
New York
United States
Corporate Office - East Coast
222 Broadway, 22nd Floor, New York, NY 10038
Financials
Total raised
$61.3M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2021 | $61.3M | Details |